Brief: Bioceltix Reports Positive Final Trial Results For Dog Drug

Bioceltix SA

13/08/2025 06:08

Aug 13 (Reuters) - Bioceltix SA BCXP.WA:

SAID ON TUESDAY FINAL RESULTS FROM CLINICAL TRIAL CONFIRMED EFFICACY AND SAFETY OF ITS BCX-CM-AD PRODUCT FOR ATOPIC DERMATITIS IN DOGS

THE STUDY MET ITS PRIMARY ENDPOINT, SHOWING A STATISTICALLY SIGNIFICANT ADVANTAGE OVER PLACEBO IN REDUCING SKIN LESIONS

THE DRUG WAS SAFE AND WELL-TOLERATED BY THE ANIMALS IN THE TRIAL

MANAGEMENT DECIDED TO CONTINUE WORKS TOWARDS AN APPLICATION FOR MARKETING AUTHORISATION WITH THE EUROPEAN MEDICINES AGENCY

 Source text for Workspace: nEM1SFfnga
 Further company coverage: BCXP.WA

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))